Chatswood, Australia

Lars Matthias Ittner

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lars Matthias Ittner: Innovator in Tauopathy Research

Introduction

Lars Matthias Ittner is a notable inventor based in Chatswood, Australia. He has made significant contributions to the field of biomedical research, particularly in the study of tauopathies, which are neurodegenerative diseases associated with the accumulation of tau protein in the brain. His innovative work has led to the development of methods and assays that could pave the way for new therapeutic approaches.

Latest Patents

Lars Matthias Ittner holds a patent for an "Assay and method for identifying compounds that reduce SIL1 expression or activity." This invention relates to methods and assays designed to identify compounds as potential candidates for drug development aimed at treating various diseases, including those associated with pathological tau. The patent also encompasses cell lines and constructs that can be utilized in the assays, providing a comprehensive approach to identifying compounds that modulate Sil1 expression or activity.

Career Highlights

Ittner is affiliated with Macquarie University, where he continues to advance his research in the field of tauopathies. His work is crucial in understanding the underlying mechanisms of these diseases and developing effective treatments.

Collaborations

Lars Matthias Ittner has collaborated with notable colleagues, including Janet Van Eersel and Arne Anselm Ittner. These collaborations enhance the research efforts and contribute to the advancement of knowledge in the field.

Conclusion

Lars Matthias Ittner's contributions to tauopathy research through his innovative patent and collaborative efforts at Macquarie University highlight his role as a significant figure in the scientific community. His work has the potential to lead to breakthroughs in the treatment of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…